Dapagliflozin in Respiratory Failure in Patients With COVID-19
Status:
Completed
Trial end date:
2021-06-11
Target enrollment:
Participant gender:
Summary
This is an international, multicenter, parallel-group, randomized, double-blind, placebo
controlled, study in hospitalized adult patients with COVID-19 in the US, Brazil, Mexico,
Argentina, India, Canada, and UK. The study is evaluating the effect of dapagliflozin 10 mg
versus placebo, given once daily for 30 days in addition to background local standard of care
therapy, on reducing complications and all-cause mortality, or improving clinical recovery.
Phase:
Phase 3
Details
Lead Sponsor:
Saint Luke's Health System
Collaborators:
AstraZeneca George Clinical Pty Ltd Saint Luke's Hospital of Kansas City